CN103842340B - 核转运调节剂及其应用 - Google Patents

核转运调节剂及其应用 Download PDF

Info

Publication number
CN103842340B
CN103842340B CN201280047930.1A CN201280047930A CN103842340B CN 103842340 B CN103842340 B CN 103842340B CN 201280047930 A CN201280047930 A CN 201280047930A CN 103842340 B CN103842340 B CN 103842340B
Authority
CN
China
Prior art keywords
ring
certain embodiments
nitrogen
members
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280047930.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103842340A (zh
Inventor
V·P·桑达纳亚卡
S·沙查姆
M·考夫曼
S·谢克特尔
D·麦考利
Y·兰德斯曼
W·塞纳佩迪斯
J-R·塞恩特-马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karyopharm Therapeutics Inc
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of CN103842340A publication Critical patent/CN103842340A/zh
Application granted granted Critical
Publication of CN103842340B publication Critical patent/CN103842340B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy
    • Y02E10/549—Organic PV cells

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN201280047930.1A 2011-07-29 2012-07-26 核转运调节剂及其应用 Active CN103842340B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161513432P 2011-07-29 2011-07-29
US201161513428P 2011-07-29 2011-07-29
US61/513,432 2011-07-29
US61/513,428 2011-07-29
US201261653588P 2012-05-31 2012-05-31
US61/653,588 2012-05-31
PCT/US2012/048368 WO2013019561A1 (en) 2011-07-29 2012-07-26 Nuclear transport modulators and uses thereof

Publications (2)

Publication Number Publication Date
CN103842340A CN103842340A (zh) 2014-06-04
CN103842340B true CN103842340B (zh) 2017-09-22

Family

ID=46682903

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280047930.1A Active CN103842340B (zh) 2011-07-29 2012-07-26 核转运调节剂及其应用

Country Status (16)

Country Link
US (4) US9428490B2 (US07794700-20100914-C00152.png)
EP (1) EP2736883B1 (US07794700-20100914-C00152.png)
JP (3) JP6006794B2 (US07794700-20100914-C00152.png)
KR (1) KR102022715B1 (US07794700-20100914-C00152.png)
CN (1) CN103842340B (US07794700-20100914-C00152.png)
AU (2) AU2016213805A1 (US07794700-20100914-C00152.png)
BR (1) BR112014001933A2 (US07794700-20100914-C00152.png)
CA (1) CA2842364A1 (US07794700-20100914-C00152.png)
CL (2) CL2014000224A1 (US07794700-20100914-C00152.png)
EA (1) EA201490406A1 (US07794700-20100914-C00152.png)
HK (1) HK1198478A1 (US07794700-20100914-C00152.png)
MX (1) MX350442B (US07794700-20100914-C00152.png)
PE (1) PE20141003A1 (US07794700-20100914-C00152.png)
SG (1) SG10201609097PA (US07794700-20100914-C00152.png)
UA (1) UA117902C2 (US07794700-20100914-C00152.png)
WO (1) WO2013019561A1 (US07794700-20100914-C00152.png)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109799A1 (en) 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
CN103402359B (zh) 2011-01-17 2016-08-24 卡尔约药物治疗公司 含烯烃核运输调节剂及其用途
CA2842364A1 (en) * 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
DK3333164T3 (da) 2011-07-29 2023-09-18 Karyopharm Therapeutics Inc Hydrazide containing nuclear transport modulators and uses thereof
LT2858991T (lt) 2012-05-09 2018-11-26 Biogen Ma Inc. Branduolinio transporto moduliatoriai ir jų panaudojimas
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
KR102545732B1 (ko) * 2013-06-21 2023-06-20 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도
TN2016000022A1 (en) 2013-07-18 2017-07-05 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
US9469650B2 (en) 2013-11-08 2016-10-18 Board Of Trustees Of The University Of Arkansas Melampomagnolide B derivatives
US9487536B2 (en) 2013-11-08 2016-11-08 Board Of Trustees Of The University Of Arkansas Melampomagnolide B derivatives
US9861615B2 (en) * 2013-11-28 2018-01-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of beta-thalassemias
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
US9790219B2 (en) 2014-03-13 2017-10-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
CN107072992B (zh) 2014-08-15 2020-03-10 卡尔约药物治疗公司 赛灵克斯的多晶型物
US9981990B2 (en) 2014-12-03 2018-05-29 Bioventures, Llc Melampomagnolide B dimers
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10344023B2 (en) 2014-12-23 2019-07-09 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2017019589A1 (en) 2015-07-24 2017-02-02 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
ES2930848T3 (es) 2015-09-23 2022-12-22 Xwpharma Ltd Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos
SG11201802798WA (en) 2015-10-06 2018-05-30 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr
CN105384673B (zh) * 2015-11-09 2017-11-14 南京富润凯德生物医药有限公司 3‑氟代‑氮杂环丁烷衍生物的合成方法
WO2017117535A1 (en) * 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2017117529A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3407885A4 (en) * 2016-01-29 2019-06-19 BioVentures, LLC TRIAZOLE DERIVATIVES OF MELAMPOMAGNOLIDE B AND METHODS OF USE THEREOF
AU2017248253B2 (en) 2016-04-07 2021-07-29 Proteostasis Therapeutics, Inc. Silicone atoms containing ivacaftor analogues
JP2019521109A (ja) * 2016-06-08 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパテ 化学化合物
AU2017280206A1 (en) 2016-06-21 2019-01-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3512515A1 (en) 2016-09-16 2019-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
CN110709386B (zh) 2017-03-30 2022-06-07 凯瑞康宁生物工程（武汉）有限公司 双环杂芳基衍生物及其制备与用途
IL275968B2 (en) 2018-01-10 2024-07-01 Xwpharma Ltd Ketamine prodrugs, preparations containing them and their uses
WO2019232724A1 (en) 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN110592141B (zh) * 2018-06-13 2023-07-07 中国科学院上海有机化学研究所 用于调控基因编辑效率的化合物及其应用
CN112004802B (zh) 2018-09-30 2021-12-28 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
JP2020141256A (ja) 2019-02-28 2020-09-03 ソニーセミコンダクタソリューションズ株式会社 復調回路、復調方法、送信装置
EP4077262B1 (en) 2019-12-20 2024-07-24 XWPharma Ltd. Methods of synthesizing 4-valyloxybutyric acid
EP4167966A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
EP4167971A1 (en) 2020-06-18 2023-04-26 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
WO2022076466A1 (en) 2020-10-05 2022-04-14 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022143779A1 (zh) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 含烯基类化合物及其应用
WO2022198033A1 (en) 2021-03-19 2022-09-22 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
CN117881394A (zh) 2021-08-13 2024-04-12 凯瑞康宁生物工程（武汉）有限公司 氯胺酮衍生物的药物组合物和口服剂型
WO2024175804A1 (en) * 2023-02-24 2024-08-29 Katholieke Universiteit Leuven Nuclear transport modulators
CN116514773A (zh) * 2023-04-24 2023-08-01 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090570A1 (en) * 2006-09-05 2009-08-19 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) * 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) * 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) * 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
CN1088062C (zh) * 1994-11-23 2002-07-24 纽罗根公司 某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US20030018025A1 (en) * 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
WO1997015567A1 (de) * 1995-10-20 1997-05-01 Dr. Karl Thomae Gmbh 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
CN1088711C (zh) * 1996-04-04 2002-08-07 盐野义制药株式会社 头孢烯化合物及含该化合物的医药
EP1360901A1 (en) 1996-04-25 2003-11-12 Nissan Chemical Industries, Limited 2,3-cyclic substituted derivatives of 3-hydroxyacrolein and 3-hydroxyacrylic acid as pesticides
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) * 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
WO1999050264A1 (fr) * 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Derives de quinazoline
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
CA2423868C (en) * 2000-09-29 2011-06-07 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
BR0212510A (pt) * 2001-09-14 2004-08-24 Methylgene Inc Inibidor de histona desacetilase, composto e composição
WO2004037248A2 (en) * 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
EP1556032A1 (en) * 2002-11-01 2005-07-27 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
WO2004043925A2 (en) * 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
CA2512886A1 (en) * 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US7667041B2 (en) * 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
JPWO2006016637A1 (ja) * 2004-08-11 2008-05-01 杏林製薬株式会社 新規環状アミノ安息香酸誘導体
WO2006088246A1 (ja) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
MY153720A (en) 2005-11-15 2015-03-13 Otsuka Pharma Co Ltd Oxazole compound and pharmaceutical composition
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
ES2452820T3 (es) * 2006-04-07 2014-04-02 Methylgene, Inc. Derivados de benzamida como inhibidores de histona desacetilasa
CN101466687B (zh) 2006-04-18 2012-04-11 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
EP2030974B1 (en) 2006-06-13 2016-02-17 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Thiazole non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
EP2054411B1 (en) * 2006-07-27 2014-08-20 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP1942104A1 (en) * 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
WO2011109799A1 (en) * 2010-03-05 2011-09-09 Karyopharm Therapeutics, Inc. Nuclear transport modulatiors and uses thereof
CN103402359B (zh) 2011-01-17 2016-08-24 卡尔约药物治疗公司 含烯烃核运输调节剂及其用途
US9152882B2 (en) * 2011-06-17 2015-10-06 Microsoft Technology Licensing, Llc. Location-aided recognition
DK3333164T3 (da) 2011-07-29 2023-09-18 Karyopharm Therapeutics Inc Hydrazide containing nuclear transport modulators and uses thereof
CA2842364A1 (en) * 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
LT2858991T (lt) 2012-05-09 2018-11-26 Biogen Ma Inc. Branduolinio transporto moduliatoriai ir jų panaudojimas
EP2968278B8 (en) * 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
US20160016916A1 (en) 2013-03-15 2016-01-21 Karyopharm Therapeutics Inc. Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
KR102545732B1 (ko) 2013-06-21 2023-06-20 카리오팜 쎄라퓨틱스, 인코포레이티드 핵수송 조절인자 및 이의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090570A1 (en) * 2006-09-05 2009-08-19 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
(E)-3-(2-(N-phenylcarbamoyl)vinyl)pyrrole-2-carboxylic acid derivatives. A novel class of glycine site antagonists;Cesarino Balsamini等;《Journal of Medicinal Chemistry》;19980214;第41卷(第6期);第810页流程1，第811页表1,第815页右栏第4段 *
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure-activity relationship and mechanism of action;Tine Van Neck等;《Bioorganic & Medicinal Chemistry》;20080920;第16卷(第21期);第9489页流程3，第9490页图4，第9490－9491页2.4部分,第9492页表1 *

Also Published As

Publication number Publication date
CL2014000224A1 (es) 2014-12-05
EA201490406A1 (ru) 2014-07-30
MX2014001180A (es) 2015-01-27
WO2013019561A1 (en) 2013-02-07
WO2013019561A8 (en) 2013-07-04
JP6752235B2 (ja) 2020-09-09
EP2736883B1 (en) 2019-09-04
US20170137430A1 (en) 2017-05-18
JP2014521653A (ja) 2014-08-28
CA2842364A1 (en) 2013-02-07
JP6006794B2 (ja) 2016-10-12
US20220056038A1 (en) 2022-02-24
US20200087313A1 (en) 2020-03-19
UA117902C2 (uk) 2018-10-25
EP2736883A1 (en) 2014-06-04
CN103842340A (zh) 2014-06-04
SG10201609097PA (en) 2016-12-29
US20150018332A1 (en) 2015-01-15
HK1198478A1 (en) 2015-05-08
CL2015001259A1 (es) 2015-07-24
NZ621520A (en) 2016-05-27
BR112014001933A2 (pt) 2017-02-21
AU2018204256A1 (en) 2018-07-05
MX350442B (es) 2017-09-06
KR102022715B1 (ko) 2019-09-18
US9428490B2 (en) 2016-08-30
PE20141003A1 (es) 2014-09-02
KR20140062480A (ko) 2014-05-23
AU2012290467A1 (en) 2014-03-13
JP2018083832A (ja) 2018-05-31
AU2016213805A1 (en) 2016-09-01
JP2016199604A (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
CN103842340B (zh) 核转运调节剂及其应用
AU2020277088B2 (en) Nuclear transport modulators and uses thereof
CN105492437B (zh) 取代的苯并呋喃基和苯并噁唑基化合物及其用途
CN103002742B (zh) 核转运调节剂及其应用
CN103402359B (zh) 含烯烃核运输调节剂及其用途
CN104478875B (zh) 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
US9938258B2 (en) Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
WO2014152263A1 (en) Exo olefin-containing nuclear transport modulators and uses thereof
AU2012290467B2 (en) Nuclear transport modulators and uses thereof
BALOGLU et al. Patent 2915365 Summary
NZ714931B2 (en) Nuclear transport modulators and uses thereof
NZ621520B2 (en) Nuclear transport modulators and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant